Business Context and Reporting Period
Company: ProKidney Corp. (PROK)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ProKidney is a late-clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy intended to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. The company operates as a single segment and has no approved products for commercial sale.
Key Corporate Event: Effective July 1, 2025, the Company completed a domestication process, changing its jurisdiction of incorporation from the Cayman Islands to the State of Delaware. This was accompanied by a restructuring of its operating subsidiaries.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $893 | $76 |
| Research & Development Expenses | $114,123 | $127,668 |
| General & Administrative Expenses | $51,777 | $56,084 |
| Net Loss (before noncontrolling interest) | $(151,612) | $(163,335) |
| Net Loss (Class A common stockholders) | $(68,986) | $(61,186) |
| Cash and Cash Equivalents (Dec 31, 2025) | $108,537 | $99,120 |
| Marketable Securities (Dec 31, 2025) | $161,480 | $259,172 |
| Total Liquidity (Cash + Securities) | $270,017 | $358,292 |
| Accumulated Deficit (Dec 31, 2025) | $(1,269,835) | $(1,200,849) |
Debt: The company has no significant long-term debt. Total liabilities as of December 31, 2025, were $34.8 million, primarily consisting of accrued expenses and lease liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $817,000 (1,075%) to $893,000, driven by a full year of leasing activities from facilities in Winston-Salem, NC, compared to only one month of activity in 2024.
- Expense Reduction: Total operating expenses decreased by $17.9 million to $165.9 million.
- R&D: Decreased by $13.5 million, primarily due to the completion or termination of certain clinical trials ($18.1M reduction) and lower professional fees related to manufacturing remediation in 2024. This was partially offset by increased costs for the ongoing Phase 3 PROACT 1 trial.
- G&A: Decreased by $4.3 million, largely due to the absence of a $5.0 million impairment charge on the Greensboro facility recognized in 2024 and lower equity-based compensation.
- Net Loss: Net loss before noncontrolling interest improved by $11.7 million to $151.6 million. Net loss attributable to Class A stockholders increased by $7.8 million to $69.0 million due to changes in the allocation of noncontrolling interest.
- Cash Flow: Net cash used in operating activities decreased to $120.1 million from $126.4 million. Net cash provided by investing activities increased significantly to $104.0 million, driven by net investment activity and the sale of the Greensboro facility ($18.2 million proceeds).
Guidance, Outlook, and Risks
Clinical Outlook:
- Phase 3 (PROACT 1): Ongoing randomized, blinded, sham-controlled study targeting ~470 patients. The FDA confirmed in July 2025 that the annualized eGFR slope can serve as a surrogate endpoint for accelerated approval. Topline data for the surrogate endpoint is anticipated in Q2 2027; confirmatory endpoint data is expected in H2 2029.
- Phase 2 (REGEN-007): Completed in May 2025. Results showed a statistically significant 78% improvement in eGFR slope in Group 1 (scheduled dosing) and a 50% improvement in Group 2 (trigger-based dosing).
Liquidity and Capital Resources:
- As of December 31, 2025, the company held approximately $270 million in cash, cash equivalents, and short-term investments.
- Management believes these resources are sufficient to fund operations and capital expenditures into mid-2027.
- The company maintains an "at-the-market" (ATM) sales agreement with Jefferies LLC, with $175 million remaining available for sale as of year-end.
Key Risks and Contingencies:
- Regulatory Approval: No products are approved; success depends on Phase 3 results and FDA approval. The novel nature of the cell therapy presents regulatory uncertainties.
- Manufacturing: The company paused manufacturing in 2023/2024 to remediate quality management system deficiencies for EU standards. Manufacturing resumed in June 2024. Risks include supply chain complexity for patient-specific therapies.
- Competition: Emerging competition from GLP-1 RAs (e.g., Ozempic) approved for kidney disease in 2025, which may impact the addressable market.
- Tax Receivable Agreement (TRA): The company is obligated to pay 85% of certain tax savings to former unitholders. While no liability was recognized as of 2025, future exchanges could trigger substantial payments.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2027" liquidity projection against current burn rates and potential capital raises.
- Phase 3 Enrollment: Monitor patient enrollment rates for the PROACT 1 trial to ensure the Q2 2027 data readout timeline remains feasible.
- Manufacturing Compliance: Confirm ongoing compliance with FDA and EMA cGMP standards following the 2024 remediation efforts.
- Competitive Landscape: Assess the impact of newly approved GLP-1 therapies on the projected market size for rilparencel.
- Tax Receivable Agreement: Review the potential financial impact of the TRA if significant unit exchanges occur in the future.